Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comprehensive evaluation on the associations between hearing and vision impairments and risk of all-cause and cause-specific dementia: results from cohort study, meta-analysis and Mendelian randomization study.
Jiang F, Dong Q, Wu S, Liu X, Dayimu A, Liu Y, Ji H, Wang L, Liu T, Li N, Li X, Fu P, Jing Q, Zhou C, Li H, Xu L, Chen S, Wang H. Jiang F, et al. Among authors: dayimu a. BMC Med. 2024 Nov 7;22(1):518. doi: 10.1186/s12916-024-03748-7. BMC Med. 2024. PMID: 39506811 Free PMC article.
Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington's disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol.
Andresen K, Cutting E, Apostolopoulos D, Evans AH, Oakley L, Dayimu A, Demiris N, Bongaerts K, Staples R, Gooding W, Rubinsztein D, Barker RA. Andresen K, et al. Among authors: dayimu a. BMJ Open. 2024 Aug 21;14(8):e087983. doi: 10.1136/bmjopen-2024-087983. BMJ Open. 2024. PMID: 39174070 Free PMC article. Clinical Trial.
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Abraham JE, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C, Drewett LM, Lucey R, Fulton A, Roberts AN, Worley JR, Chhabra A, Qian W, Vallier AL, Hardy RM, Chan S, Hickish T, Tripathi D, Venkitaraman R, Persic M, Aslam S, Glassman D, Raj S, Borley A, Braybrooke JP, Sutherland S, Staples E, Scott LC, Davies M, Palmer CA, Moody M, Churn MJ, Newby JC, Mukesh MB, Chakrabarti A, Roylance RR, Schouten PC, Levitt NC, McAdam K, Armstrong AC, Copson ER, McMurtry E, Tischkowitz M, Provenzano E, Earl HM. Abraham JE, et al. Among authors: dayimu a. Nature. 2024 May;629(8014):1142-1148. doi: 10.1038/s41586-024-07384-2. Epub 2024 Apr 8. Nature. 2024. PMID: 38588696 Free PMC article. Clinical Trial.
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Dayimu A, Gupta A, Matin RN, Nobes J, Board R, Payne M, Rao A, Fusi A, Danson S, Eccles B, Carser J, Brown CO, Steven N, Bhattacharyya M, Brown E, Gonzalez M, Highley M, Pickering L, Kumar S, Waterston A, Burghel G, Demain L, Baker E, Wulff J, Qian W, Twelves S, Middleton M, Corrie P. Dayimu A, et al. Eur J Cancer. 2024 Jan;196:113455. doi: 10.1016/j.ejca.2023.113455. Epub 2023 Nov 24. Eur J Cancer. 2024. PMID: 38029480 Free article. Clinical Trial.
Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma.
Mehta I, Dayimu A, Kumar S, Boobier C, Oladipo O, Burke D, Olson-Brown A, Yesildag P, Nobes J, Brown S, Booth C, Wheater M, Muller D, Fountain V, Ford L, Board R, McGurk L, Twelves S, Demiris N, Corrie P. Mehta I, et al. Among authors: dayimu a. Eur J Cancer. 2023 Nov;194:113344. doi: 10.1016/j.ejca.2023.113344. Epub 2023 Sep 17. Eur J Cancer. 2023. PMID: 37804771
17 results